PROWESS study

The PROWESS study was a clinical trial that evaluated the effectiveness of a medication called activated protein C (Drotrecogin alfa) in treating severe sepsis, a life-threatening condition caused by infections. Conducted in the early 2000s, the study aimed to determine if this treatment could reduce mortality rates in patients with sepsis. The results showed that it did significantly lower the risk of death, leading to its approval for use in such patients. However, further research later revealed concerns about its safety and cost, leading to its eventual withdrawal from the market.